CN104592111A - Synthesis method of montelukast intermediate - Google Patents
Synthesis method of montelukast intermediate Download PDFInfo
- Publication number
- CN104592111A CN104592111A CN201510080010.5A CN201510080010A CN104592111A CN 104592111 A CN104592111 A CN 104592111A CN 201510080010 A CN201510080010 A CN 201510080010A CN 104592111 A CN104592111 A CN 104592111A
- Authority
- CN
- China
- Prior art keywords
- reaction
- compound
- synthetic method
- montelukast sodium
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title abstract 4
- 229960005127 montelukast Drugs 0.000 title abstract 4
- 238000001308 synthesis method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 12
- 150000004756 silanes Chemical class 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 7
- 239000007818 Grignard reagent Substances 0.000 claims abstract description 4
- 150000004795 grignard reagents Chemical class 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 44
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 22
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 15
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims description 15
- 229960001951 montelukast sodium Drugs 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 14
- 238000010189 synthetic method Methods 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical group C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000007810 chemical reaction solvent Substances 0.000 claims description 8
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical group [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 claims description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 239000005051 trimethylchlorosilane Substances 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 claims description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 15
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 229940095102 methyl benzoate Drugs 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- 238000003756 stirring Methods 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- -1 chloro-2-quinolyl Chemical group 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 239000007789 gas Substances 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N anhydrous methyl chloride Natural products ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000001650 tertiary alcohol group Chemical group 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510080010.5A CN104592111B (en) | 2015-02-13 | 2015-02-13 | A kind of synthetic method of montelukast sodium intermediate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510080010.5A CN104592111B (en) | 2015-02-13 | 2015-02-13 | A kind of synthetic method of montelukast sodium intermediate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104592111A true CN104592111A (en) | 2015-05-06 |
CN104592111B CN104592111B (en) | 2015-11-11 |
Family
ID=53118217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510080010.5A Active CN104592111B (en) | 2015-02-13 | 2015-02-13 | A kind of synthetic method of montelukast sodium intermediate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104592111B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008035086A2 (en) * | 2006-09-22 | 2008-03-27 | Almac Sciences Limited | Synthesis of leukotriene compounds |
CN102424673A (en) * | 2011-09-14 | 2012-04-25 | 浙江海正药业股份有限公司 | Montelukast sodium intermediate and method for synthesizing montelukast sodium thereof |
-
2015
- 2015-02-13 CN CN201510080010.5A patent/CN104592111B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008035086A2 (en) * | 2006-09-22 | 2008-03-27 | Almac Sciences Limited | Synthesis of leukotriene compounds |
CN102424673A (en) * | 2011-09-14 | 2012-04-25 | 浙江海正药业股份有限公司 | Montelukast sodium intermediate and method for synthesizing montelukast sodium thereof |
Also Published As
Publication number | Publication date |
---|---|
CN104592111B (en) | 2015-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010503694A5 (en) | ||
CN104610254A (en) | Low-cost preparation method for palbociclib | |
JP2001508468A (en) | Preparation of monofluoromethyl ether | |
CN103420801B (en) | Method for preparing pentafluorophenol | |
CN107556302A (en) | It is a kind of to prepare the net methods of Yi Palie | |
CN104592111B (en) | A kind of synthetic method of montelukast sodium intermediate | |
CN104080791A (en) | Methods of isolating (4-chloro-2-fluoro-3-substituted-phenyl) boronates and methods of using the same | |
CN102924548B (en) | Synthesis method of capecitabine | |
CN104788483B (en) | A method of preparing phenylboronic acid ortho- meta- and para-substituted with hydroxy and mercapto | |
CN107987097B (en) | The synthesis technology of 2,6- dichloropyridine -4- boric acid pinacol ester | |
CN1085208C (en) | Process for preparing eprosartan | |
CN110483433A (en) | The synthetic method of 4- methyl -5- ethyoxyl oxazole acetoacetic ester | |
CN101928219B (en) | Method for preparing ethyl 2-oxo-4-phenylbutyrate | |
CN114835614A (en) | Preparation process of 1-mercaptomethylcyclopropyl acetic acid | |
CN101550134B (en) | Method for preparing 2-[1H-pyrazole-5-radical]-4H-3, 1-benzoxazine-4-ketone compound | |
CN106008302B (en) | A kind of vitamin D2The preparation method of derivative | |
CN103145553B (en) | The Synthesis and application of 2,3-Hydrocarbyl-substituted succinic acid diesters | |
EP2011571B1 (en) | The process for producing isocyanato-alkyl silane | |
CN103159704B (en) | Cabazitaxel intermediates and cabazitaxel intermediate preparation method | |
CN109422698B (en) | Preparation method of amine compound | |
CN109265329B (en) | Preparation method of 3, 5-dichloro-2-pentanone | |
CN104211600A (en) | Preparation method of 3,5-binitro-o-methylbenzoyl chloride as liquid-state dinitolmide intermediate | |
CN113045523A (en) | Preparation method of imidazoline pyridine compound intermediate | |
CN1835918A (en) | Process for the preparation of racemic 2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[4-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]-propanoic acid | |
CN108358797A (en) | A kind of synthetic method of alkyl glycine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 223800 Suqian ecological Chemical Industry Park Management Committee, Suyu District, Jiangsu, Suqian Patentee after: Jiangsu Furui Kangtai Pharmaceutical Co.,Ltd. Address before: 223800 Suqian ecological Chemical Industry Park Management Committee, Suyu District, Jiangsu, Suqian Patentee before: JIANGSU OCEAN PHARMACEUTICAL AND CHEMICAL ENGINEERING CO.,LTD. |
|
CP03 | Change of name, title or address |
Address after: 223800 Suqian Eco-chemical Science and Technology Industrial Park, Suqian City, Jiangsu Province Patentee after: Jiangsu Alpha Group Furui Pharmaceutical (Suqian) Co.,Ltd. Country or region after: China Address before: 223800 Suqian Eco-chemical Science and Technology Industrial Park, Suqian City, Jiangsu Province Patentee before: Jiangsu Furui Kangtai Pharmaceutical Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |